Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

21.11.2019 | short review

Surgery in renal cell carcinoma—when, whom and how?

verfasst von: Sebastian Lenart, MD, Ingrid Berger, Nikolaus Hartig, Stephan Madersbacher, Anton Ponholzer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Summary

Surgical resection of RCC should be the aim for cure of localized or locally advanced RCC, either by partial or radical nephrectomy, depending on tumor size and patient’s performance status. In cT1 stages partial nephrectomy is recommended. In metastatic stage, immediate CN can be performed in patients with good performance status, who do not need systemic therapy because of oligometatastic disease with feasibility of complete resection.
Literatur
1.
MacLennan S, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol. 2012;61(5):972–93.PubMed
2.
Gill IS, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007;178(1):41–6.PubMed
3.
Marszalek M, et al. Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. Eur Urol. 2009;55(5):1171–8.PubMed
4.
Hemal AK, et al. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol. 2007;177(3):862–6.PubMed
5.
Tait C, et al. Long-term oncologic outcomes of laparoscopic radical nephrectomy for kidney cancer resection: Dundee cohort and metaanalysis of observational studies. Surg Endosc. 2011;25(10):3154–61.PubMed
6.
7.
Bianchi M, et al. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urol Oncol. 2014;32(1):46e1–46e7.
8.
Van Poppel H, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52.PubMed
9.
Abdollah F, et al. Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephron-sparing surgery in contemporary North American patients with renal cell cancer. BJU Int. 2018;121(3):345–7.PubMed
10.
Scosyrev E, et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol. 2014;65(2):372–7.PubMed
11.
MacLennan S, et al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol. 2012;62(6):1097–117.PubMed
12.
Woldu SL, et al. Who really benefits from nephron-sparing surgery? Urology. 2014;84(4):860–7.PubMed
13.
Larcher A, et al. Elective nephron sparing surgery decreases other cause mortality relative to radical nephrectomy only in specific subgroups of patients with renal cell carcinoma. J Urol. 2016;196(4):1008–13.PubMed
14.
Weight CJ, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol. 2010;183(4):1317–23.PubMed
15.
Lane BR, et al. Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate. Eur Urol. 2015;68(6):996–1003.PubMed
16.
Bagrodia A, et al. Comparison of rates and risk factors for development of osteoporosis and fractures after radical or partial nephrectomy. Urology. 2011;78(3):614–9.PubMed
17.
Woldrich J, et al. Comparison of rates and risk factors for development of anaemia and erythropoiesis-stimulating agent utilization after radical or partial nephrectomy. BJU Int. 2012;109(7):1019–25.PubMed
18.
Capitanio U, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur Urol. 2015;67(4):683–9.PubMed
19.
Gong EM, et al. Comparison of laparoscopic and open partial nephrectomy in clinical T1a renal tumors. J Endourol. 2008;22(5):953–7.PubMed
20.
Peng, B., et al., Retroperitoneal laparoscopic nephrectomy and open nephrectomy for radical treatment of renal cell carcinoma: A comparison of clinical outcomes. Acad J Second Mil Med Univ. 2006;27:1167–1169
21.
Gratzke C, et al. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU Int. 2009;104(4):470–5.PubMed
22.
Asimakopoulos AD, et al. Robotic radical nephrectomy for renal cell carcinoma: a systematic review. BMC Urol. 2014;14:75.PubMedPubMedCentral
23.
Jeong IG, et al. Association of robotic-assisted vs laparoscopic radical nephrectomy with Perioperative outcomes and health care costs, 2003 to 2015. JAMA. 2017;318(16):1561–8.PubMedPubMedCentral
24.
Masson-Lecomte A, et al. A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy. Urol Oncol. 2013;31(6):924–9.PubMed
25.
Peyronnet B, et al. Comparison of 1800 robotic and open partial nephrectomies for renal tumors. Ann Surg Oncol. 2016;23(13):4277–83.PubMed
26.
Choi JE, et al. Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur Urol. 2015;67(5):891–901.PubMed
27.
Noone AM, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomarkers Prev. 2017;26(4):632–41.PubMed
28.
Levy DA, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159(4):1163–7.PubMed
29.
Lam JS, et al. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005;6(1):7–18.PubMed
30.
Bissada NK, et al. Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology. 2003;61(1):89–92.PubMed
31.
Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol. 2004;171(2):598–601.PubMed
32.
Lardas M, et al. Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus. Eur Urol. 2016;70(2):265–80.PubMed
33.
Wotkowicz C, et al. Management of renal cell carcinoma with vena cava and atrial thrombus: minimal access vs median sternotomy with circulatory arrest. BJU Int. 2006;98(2):289–97.PubMed
34.
Maxwell NJ, et al. Renal artery embolisation in the palliative treatment of renal carcinoma. Br J Radiol. 2007;80(950):96–102.PubMed
35.
Blom JH, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55(1):28–34.PubMed
36.
Gershman B, et al. Radical nephrectomy with or without lymph node dissection for high risk nonmetastatic renal cell carcinoma: a multi-institutional analysis. J Urol. 2018;199(5):1143–8.PubMed
37.
Zareba P, Pinthus JH, Russo P. The contemporary role of lymph node dissection in the management of renal cell carcinoma. Ther Adv Urol. 2018;10(11):335–42.PubMedPubMedCentral
38.
Flanigan RC, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.PubMed
39.
Mejean A, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–27.PubMed
40.
41.
Dabestani S, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15(12):e549–e61.PubMed
42.
Ouzaid I, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019;2(2):141–9.PubMed
Metadaten
Titel
Surgery in renal cell carcinoma—when, whom and how?
verfasst von
Sebastian Lenart, MD
Ingrid Berger
Nikolaus Hartig
Stephan Madersbacher
Anton Ponholzer
Publikationsdatum
21.11.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00548-1

Weitere Artikel der Ausgabe 4/2019

ASCO 2019: highlights in HER2-positive metastatic breast cancer

  • Open Access
  • review

Current trends in small cell lung cancer management—ASCO 2019 update

  • short review

HPV-associated cancers

  • Open Access
  • short review

Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?

  • Open Access
  • short review

Targeted therapy in lung cancer—ASCO 2019 update

  • Open Access
  • short review

Neoadjuvant therapy in urothelial cancer

  • Open Access
  • short review

Neu im Fachgebiet Onkologie

Weniger PSA-Screening, mehr fortgeschrittene Tumoren

Eine Empfehlung gegen das Prostatakrebs-Screening, die mehrere Jahre in den Leitlinien des Royal Australasian College of General Practitioners gegeben wurde, hat sich nicht nur auf die Rate von PSA-Tests negativ ausgewirkt.

Schützt kutane Autoimmunität vor Hauttumoren?

Schwedische Registerdaten deuten auf ein geringeres Risiko für bestimmte Hauttumoren bei Personen mit Vitiligo oder autoimmuner Alopezie. Wie es dazu kommt, ist dagegen unklar.

Muss man wirklich auch die letzte Krebszelle eliminieren?

Genauere Prognoseabschätzung, bessere Therapiesteuerung und eine schnellere Entwicklung innovativer Behandlungsansätze – der Messung der minimalen Resterkrankung (MRD) wird ein enormes Potenzial attestiert. Eine Übersichtsarbeit unterstreicht jetzt aber: Es gibt noch blinde Flecken.

Zufällig entdeckter Barrett-Ösophagus nicht weniger risikobehaftet

Fälle von Barrett-Ösophagus, die bei einer ÖGD als Zufallsbefund zutage treten, sind keine Seltenheit und auch keineswegs harmloser als Barrett-Metaplasien, die bei gezieltem Screening oder Surveillance-Untersuchungen entdeckt werden. 

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise